Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

SCYNEXIS Inc (SCYX) Has Some Pent Up Buy Volume Waiting To Pull The Trigger

SCYNEXIS Inc. (NASDAQ:SCYXpicked up some strength on Monday, and after a relatively flat day on Tuesday is back to making solid gains today on positive sentiment, being up by over 7.5%. The gains come on the back of expectations for a near term binary event – the releasing of some data from two concurrent trials of its lead candidate – and it seems markets expect this data to come out in favor of continued development.

The drug in question is called SCY-078, and the trials are the follow on sections of two phase II studies, with targets that we will look at in a little more detail shortly. Back at the beginning of end of July/beginning of August, the company announced that this data would be available by the end of the third quarter of 2016.

Of course, this timeframe has now passed, and so markets expect the data any day now. The trial has already been reported as meeting its objectives, and so the follow on data is expected to mirror this outcome. As mentioned, if it does, there’s plenty of potential upside on offer, above and beyond the current gains, on the advancing of the drug into a pivotal trial in this indication.


The market is large, and for us this validates this bias.

With this in mind, here’s a look at the drug and the indications in question, and a discussion of what we are looking for from the phase II follow ups as reinforcing of an efficacy bias, and in turn, a bullish near term thesis.

Follow Scynexis Inc (NASDAQ:SCYX)
Trade (NASDAQ:SCYX) Now!

So, SCY-078 is targeting tow primary conditions, both caused by a Candida infection – a condition called vulvovaginal candidiasis (VVC) and another called invasive candidiasis. Both are conditions that often get referred to as a yeast infection, and they are very common – nearly 75% of all adult women have had at least one incidence of an infection caused by the underlying yeast, Candida, in their lifetime.

The current SOC treatments are topical (creams) or an antibacterial vaginal suppository. These methods of treatments are safe and effective in most of the mild forms of the condition, but in IC and VVC a stronger treatment is often required to avoid recurrence.

This is where SCY-078 comes in. It’s an oral and an IV treatment, which works by inhibiting what is called beta 1,3 D glucan synthesis in the cell wall of fungi. The inhibition of this process results in fungicidal cell death, and the countering of the infection in question.

In the IC indication, patients received IV dose of an SOC called, echinocandin, and then stepped down onto a once daily dose of oral SCY-078. 86% of those randomized to the drug, at the point of the analysis, looked as though they were set for a positive result. It is this 865 we are watching closely when the upcoming data hits, to see if the drug has maintained its edge over non randomization.

In the VVC trial, the company managed to demonstrate that SCY-078 exhibited clinical evidence of the antifungal activity of oral SCY-078 in an infection caused by Candida, and in turn, met on its efficacy endpoint. Again, we are looking for a maintenance of this efficacy (i.e. no or few recurrences of the infections) in the patients in question.

What sort of upside is on the cards if the SCYNEXIS Inc. (NASDAQ:SCYX) can put out positive follow up data?

Well, the company didn’t respond too positively to the July release, and we think this is representative of markets waiting for confirmation by way of follow up. In light of this, we think there’s plenty of pent up buy volume waiting to pull the trigger, and that the recent gains illustrate this pressure.

As such, we put a 20-30% minimum upside on positive data, with a target somewhere in the region of $5.60 a share.

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!